Huntsman: Q1 Is Further Evidence The Bottom Is In

Huntsman remains a buy as sequential improvement is expected from tighter global supply and gradually recovering end markets. Q1 volumes were resilient, Advanced Materials margins expanded, and cost cuts plus Middle East supply disruptions are providing early support. Leverage is elevated at 6.1x due to depressed EBITDA, but liquidity is solid with a new $800M revolver and $369M in cash.

Analysis

The setup is less about a clean cyclical snapback and more about operating leverage off a trough EBITDA base. That matters because even modest sequential volume improvement can produce disproportionately sharp equity upside while the market is still anchoring on a high leverage multiple; in other words, the stock can rerate faster than credit de-risks. The near-term winners are peers with less balance-sheet strain but similar exposure to specialty chemical demand, because Huntsman’s commentary implicitly validates that the broader channel is turning without signaling a full end-market recovery yet.

The most important second-order effect is supply-side discipline. Any disruption in Middle East-linked supply tends to tighten regional pricing first, then flow through global contract resets with a lag, which can support margins for 1-2 quarters even if underlying demand is only flat-to-slightly up. That creates a window where competitors with higher variable-cost structures or less diversified feedstock exposure may be forced to protect share at the expense of margin.

The main risk is that the current optimism is front-running an actual demand inflection by several months. If industrial activity softens again or distributors destock after the initial restock phase, the EBITDA bounce can stall quickly and leverage optics worsen despite cash preservation. The market is likely underweighting how sensitive the equity is to a small change in absolute EBITDA at 6x+ leverage: a 10% miss in EBITDA can have a much larger impact on perceived solvency than on operating performance.

Contrarianly, the setup may be better for relative value than outright directional exposure. The market appears to be treating this as a generic cyclical recovery, but the real edge is in timing the margin recovery versus the balance-sheet repair cycle. If management continues to execute on cost actions, the stock can grind higher over the next 3-6 months even without a strong macro tape, but the upside likely caps out unless end-market volumes show sustained inflection into year-end.

Key Decisions for Investors

• Go long HUN on weakness over the next 1-3 weeks; target a 3-6 month hold. Best risk/reward is if the stock trades at a discount to implied 2025 EBITDA recovery while liquidity concerns remain overdone.
• Pair trade: long HUN / short a more domestically exposed cyclical chemical name with weaker margin flexibility for 1-2 quarters. The trade should capture relative margin expansion from supply tightness while reducing beta to broad industrial demand.
• Use call spreads rather than common stock for HUN over the next 3-6 months. A modestly bullish structure limits downside if the recovery stalls while preserving upside if EBITDA revisions start to move higher.
• Take profit on any sharp 10-15% rally unless subsequent monthly order data confirms sustained demand improvement. The leverage overhang means the stock can reprice quickly, but the same leverage also makes the move fragile.
• Do not chase after a gap-up day; wait for either a pullback or confirmation that sequential margin gains are holding. The key catalyst is not the quarter itself, but whether management can sustain pricing power into the next two reporting periods.